Sample collection for evaluation of the Panbio™ COVID-19/ Flu A&B test
Research type
Research Study
Full title
Sample collection for evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel
IRAS ID
312115
Contact name
Raza Mohammad
Contact email
Sponsor organisation
Abbott Rapid Dx International Limited
Clinicaltrials.gov Identifier
Duration of Study in the UK
0 years, 11 months, 2 days
Research summary
Research Summary:
Flu and COVID-19 are both contagious respiratory illnesses, they share some similar symptoms but are caused by different viruses. Because some of the symptoms of flu and COVID-19 are similar, the difference between them cannot be made based on symptoms alone. Testing is needed to tell what the illness is and to confirm a diagnosis.
The Panbio™ COVID-19 / Flu A&B Rapid Panel is a rapid test device that can detect both flu and COVID-19 viruses at the same time and within 15-20 minutes.
This study is intended to collect fluid samples from people's noses to investigate and evaluate how well this test performs in finding COVID-19 and flu virus in the samples taken from people. To do this, we will use an approved test method as a reference to compare to the test result of the Panbio test. With sufficient data and appropriate analysis, we would be able to tell how well this device performs.
This is a global study, we aim to include at least 665 patients with symptoms of flu or COVID-19 to take part in the study. Each participant will be asked to have three nose swabs (two different types) taken by their healthcare professional.
The study is funded by Abbott Rapid Diagnostics.
REC name
London - Brent Research Ethics Committee
REC reference
22/HRA/0436
Date of REC Opinion
7 Mar 2022
REC opinion
Favourable Opinion